A new self-rating scale for detecting atypical or second-generation antipsychotic side effects

Waddell, Linda; Taylor, Mark

doi:10.1177/0269881107087976

Cited by 126 publications

(137 citation statements)

References 11 publications

(12 reference statements)

Supporting

Mentioning

136

Contrasting

Order By: Relevance

“…For instance, Waddington et al [43] found that antipsychotic polypharmacy is associated with increased mortality and reduced survival among patients with schizophrenia. In addition, newer outcome measures such as the Glasgow Antipsychotic Side-effect Scale must be taken into consideration for future assessments, which has been structured for detecting the side effects of SGAs and has shown to have good discriminatory power and construct validity, along with good test/re-test reliability [44]. Some of the limitations of this study could be summarized as follows: (1) small sample size; (2) no direct comparison between flupenthixol decanoate and aripiprazole regarding their individual therapeutic efficacy; (3) the short duration of the study; and (4) gender-based sampling.…”

Section: Discussionmentioning

confidence: 99%

Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study

Shafti

2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study

Shafti

2017

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

“…The tolerability-related burden associated with these AEs may lead to poor adherence or earlier treatment discontinuation and, as a result, worse functional outcomes [2,11,12]. Several observer-reported and self-reported AE assessment scales for antipsychotic medications are available [2,13–17]. Self-reported scales include the Udvalg for Kliniske Undersøgelser (UKU) Side-Effect Rating Scale, the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS), and the Glasgow Antipsychotic Side-Effect Scale (GASS).…”

Section: Introductionmentioning

confidence: 99%

“…As such, the LUNSERS cannot be readily used to compare the tolerability profiles of antipsychotics and has not been included in many pivotal studies. The GASS resolves some ambiguity of phrasing in the LUNSERS [2] and enables patients to report whether an AE is ‘distressing’ in addition to rating its severity [17]; however, like the LUNSERS, the GASS contains only a subset of the AEs that can occur with antipsychotics and therefore has limited utility. Another approach to estimating AEs is to consider the subjective nature of the AE.…”

Section: Introductionmentioning

confidence: 99%

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

François

Guiraud-Diawara²,

Lançon³

et al. 2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background: Adverse event (AE) reporting in clinical trials does not fully capture the patient-level perspective and comparing tolerability across treatments or among studies is difficult. Objective: This study was designed to develop a treatment tolerability index algorithm that combines AE reporting with physician- and patient-level AE information into a global burden score to allow comparison of the overall tolerability of antipsychotic medications used in treating schizophrenia. Study design: Data from a 4-arm, placebo-controlled clinical trial were used in the proposed tolerability index algorithm. For each patient, AEs were adjusted by frequency, severity, duration, and patient-experienced importance, and average tolerability-related burden scores were calculated. Setting: Algorithm development analyses. Patients: This study analyzed data from a previously completed clinical trial that evaluated a potential antipsychotic medication; no patients were involved in the current study. Intervention: No interventions were administered in this study; the analyses described used data derived from a previously completed clinical trial in which patients received bifeprunox, risperidone, or placebo. Main outcome measure: Burden scores and tolerability index scores were compared for patients who did or did not discontinue treatment because of AEs. Results: The number of AEs varied widely among patients. Burden scores were significantly worse for patients who discontinued treatment because of AEs. Mean tolerability index scores, adjusted based on AE frequency, severity-adjusted duration, and patient-experienced impact, were poorer for active medications than placebo, and increased with dose. Conclusion: The treatment tolerability index will allow comparison of AE burden and tolerability between treatments using existing clinical trial information. This suggests that scoring is possible, is clinically relevant, and allows standardized comparison of antipsychotic tolerability.

show abstract

“…Patients provide their responses to these questions by circling relevant side effects. An additional open question enquires about any other possible side effects [31].…”

Section: Introductionmentioning

confidence: 99%

“…The GASS takes 5 minutes to complete (21 items for men and women) and contains self-explanatory questions in everyday plain English while providing a structured systematic method of reviewing antipsychotic side effects [31].…”

Section: Introductionmentioning

confidence: 99%

Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in Greece

Nystazaki¹

2014

JPCPY

View full text Add to dashboard Cite

The aim of the present study was to evaluate the linguistic adaptation and psychometric validation into the Greek language of the GASS scale for the assessment of side effects in patients treated with second generation antipsychotic medication. The GASS scale takes 5 minutes to complete (21 items for men and women) and contains self-explanatory questions in everyday plain English while providing a structured systematic method of reviewing antipsychotic side effects. The translation and cultural adaptation of the questionnaire was performed according to international standards. Internal consistency using the Cronbach α coefficient and test-retest reliability using the intraclass correlation coefficient (ICC) was used to assess the reliability of the instrument. Patient's sample consisted of 80 participants with a mean age of 42.6 years. Internal consistency and intraclass correlation coefficient were adequate (Cronbach α = 0.79 and ICC = 0.96). The test-retest percent agreement for the aforementioned categories was 95.9. Agreement was satisfactory according to Kappa coefficient which was equal to 0.78 (p<0.001).The Greek validation of the GASS scale shows appropriate feasibility, reliability, and discriminative performance as a patient-reported outcome to be used for the assessment of the impact of side effects on patients with schizophrenia.

show abstract

A new self-rating scale for detecting atypical or second-generation antipsychotic side effects

Cited by 126 publications

References 11 publications

Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study

Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting

Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in Greece

Contact Info

Product

Resources

About